In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

TG Therapeutics Inc (NASDAQ: TGTX) closed the day trading at $26.71 down -4.23% from the previous closing price of $27.89. In other words, the price has decreased by -$4.23 from its previous closing price. On the day, 4.79 million shares were traded. TGTX stock price reached its highest trading level at $27.92 during the session, while it also had its lowest trading level at $26.52.

Ratios:

For a better understanding of TGTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.86. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.

On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.

Goldman Upgraded its Sell to Neutral on August 02, 2023, whereas the target price for the stock was revised from $16 to $12.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 13 ’25 when Echelard Yann sold 10,000 shares for $36.94 per share. The transaction valued at 369,400 led to the insider holds 228,816 shares of the business.

Echelard Yann bought 10,000 shares of TGTX for $369,348 on Jun 13 ’25. On Jan 03 ’25, another insider, Power Sean A, who serves as the CFO of the company, sold 11,337 shares for $30.29 each. As a result, the insider received 343,443 and left with 670,632 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 4240346112 and an Enterprise Value of 3873088000. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.38, and their Forward P/E ratio for the next fiscal year is 15.51. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.34 while its Price-to-Book (P/B) ratio in mrq is 15.27. Its current Enterprise Value per Revenue stands at 8.53 whereas that against EBITDA is 45.097.

Stock Price History:

The Beta on a monthly basis for TGTX is 1.91, which has changed by 0.2934625 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is -25.92%, while the 200-Day Moving Average is calculated to be -21.84%.

Shares Statistics:

Over the past 3-months, TGTX traded about 1.98M shares per day on average, while over the past 10 days, TGTX traded about 3600620 shares per day. A total of 158.03M shares are outstanding, with a floating share count of 142.98M. Insiders hold about 9.93% of the company’s shares, while institutions hold 62.61% stake in the company. Shares short for TGTX as of 1752537600 were 24169314 with a Short Ratio of 12.21, compared to 1749772800 on 23697171. Therefore, it implies a Short% of Shares Outstanding of 24169314 and a Short% of Float of 19.91.

Earnings Estimates

The stock of TG Therapeutics Inc (TGTX) is currently being evaluated by 5.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.32, with high estimates of $0.43 and low estimates of $0.21.

Analysts are recommending an EPS of between $0.96 and $0.53 for the fiscal current year, implying an average EPS of $0.76. EPS for the following year is $1.72, with 5.0 analysts recommending between $2.49 and $1.04.

Revenue Estimates

6 analysts predict $152.95M in revenue for the current quarter. It ranges from a high estimate of $157.5M to a low estimate of $150M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $83.88MFor the next quarter, 6 analysts are estimating revenue of $174.39M. There is a high estimate of $178.39M for the next quarter, whereas the lowest estimate is $170.4M.

A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $593M, while the lowest revenue estimate was $582.8M, resulting in an average revenue estimate of $588.95M. In the same quarter a year ago, actual revenue was $329MBased on 7 analysts’ estimates, the company’s revenue will be $830.81M in the next fiscal year. The high estimate is $927M and the low estimate is $692.6M.